Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT2CK17 for Antidepressant Adherence in Depression
NCT03388164Phase 2Terminated
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram + RT2CK17 with Escitalopram + Placebo (2 arms). Primary endpoint: Rate of Adherence at 8 weeks. Started Jan 2018; status: terminated.
02
Drugs
riboflavin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03388164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388164.